PublishedHealthcare & Life SciencesDiagnostics & MonitoringGlobal

Digital Pathology Market Report: Size, Share & Trends 2026–2035

Digital Pathology Market by Product (Software & Analytics, Scanners, Storage & Communication Systems, Services), by Application (Cancer Diagnosis, Drug Discovery & Development, Disease Research, Others (Education and training, clinical diagnostics for non-cancer disease, and veterinary/forensic pathology)), by End User (Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Academic & Research Institutes), by Deployment (On-Premise, Cloud-Based, Hybrid), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035

Author: Sneha ReddyReviewed by: Sunil BhosaleFact CheckedPublished:
Report codeVMI-1-3-37694
PublishedNovember 2026
Pages300+
Tables / figures96 / 70
Historical2023–2025
Base year2025
Forecast2026–2035
FormatPDF

Digital Pathology Industry Perspective

The Global Digital Pathology market was valued at USD 1,378.5 Mn in 2025 and is projected to reach USD 4,175.6 Mn by 2035, growing at a CAGR of 11.72% across the 2026–2035 forecast period, according to Vectomat Insights.

North America is the largest regional market with a 40.0% revenue share, and Software & Analytics is the dominant product category at 42.0%, while hospitals and diagnostic labs, already 50.0% of end-user revenue, are moving primary diagnosis from the microscope to the screen.

Market size 2025USD 1,378.5 Mn
Forecast 2035USD 4,175.6 Mn
CAGR 2026–203511.72%
Largest regionNorth America40% share · fastest: Asia Pacific

Digital Pathology Market: Overview

Digital pathology encompasses the hardware, software and services that convert stained tissue slides into high-resolution whole-slide images and carry those images through review, analysis, archiving and reporting. The report scope spans four product categories (Software & Analytics, Scanners, Storage & Communication Systems and Services), applications from cancer diagnosis to drug discovery and disease research, and on-premise, cloud-based and hybrid deployment models.

The value chain runs across three tiers. Foundational providers build the scanners and imaging hardware, led by Leica Biosystems, Hamamatsu Photonics and Philips. Specialist developers supply the image management platforms and workflow layer that sit between scanner and pathologist, including Roche Diagnostics, Sectra and Proscia. Application-layer specialists sell the AI algorithms that detect, grade and quantify disease on those images, with PathAI, Ibex Medical Analytics and Aiforia Technologies among the most widely deployed.

For procurement and investment teams, value is concentrating in software that sits on top of an installed scanner base, in cloud and hybrid archives, and in hospital and reference-lab networks converting to fully digital sign-out. This report tracks those shifts across 4 segmentation dimensions and 35+ countries, so buyers can see which sub-segments and geographies capture outsized share of the forecast growth.

According to International Agency for Research on Cancer (IARC), GLOBOCAN 2022, February 2024, An estimated 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, each new case typically requiring at least one histopathology review.

Digital pathology market at a glance — USD 1,378.5 Mn (2025) to USD 4,175.6 Mn, 11.72% CAGR | Vectomat Insights
The Digital Pathology market triples to USD 4,175.6 Mn by 2035, led by North America and Software & Analytics. Source: Vectomat Insights, Digital Pathology Market Report.

Key Insights

  • The Global Digital Pathology market rises from USD 1,378.5 Mn in 2025 to USD 4,175.6 Mn by 2035, an 11.72% CAGR that roughly triples the market inside the forecast horizon.
  • Software & Analytics is the dominant product segment at 42.0% of 2025 revenue (USD 579.0 Mn), because image management, viewing and AI licences recur every year while scanners are bought once.
  • Storage & Communication Systems is the fastest-growing product segment at a 17.41% CAGR, lifting its revenue from USD 193.0 Mn in 2025 to USD 960.5 Mn by 2035 as whole-slide image archives swell.
  • Cancer Diagnosis is the dominant application at 46.0% of 2025 revenue (USD 634.1 Mn), since prostate, breast and gastrointestinal biopsies are where FDA-cleared and CE-IVD algorithms are most mature.
  • Hospitals & Diagnostic Labs are the dominant end user at 50.0% of 2025 revenue and also the fastest-growing at a 15.14% CAGR, driven by pathologist shortages and the shift to remote sign-out.
  • North America leads all regions with a 40.0% share in 2025 (USD 551.4 Mn), and the United States alone accounts for USD 452.1 Mn.
  • Asia Pacific is the fastest-growing region, with South Korea forecast at a 13.9% CAGR and Japan at 12.0%, both ahead of the United States at 10.5%.
  • Consolidation is redrawing the vendor map: Roche agreed to acquire PathAI for up to USD 1.05 Bn in May 2026, and Agilent completed its purchase of Proscia, agreed in October 2026 for up to USD 270 Mn.
  • Hybrid deployment is the fastest-growing model at an 18.0% CAGR, and VMI expects cloud and hybrid together to exceed 65% of deployment revenue by 2035 as labs move archives off local servers.
Digital pathology market size — USD 1,378.5 Mn (2025) to USD 4,175.6 Mn (2035), 11.72% CAGR | Vectomat Insights
The Global Digital Pathology market grows from USD 1,378.5 Mn in 2025 to USD 4,175.6 Mn by 2035, an 11.72% CAGR. Source: Vectomat Insights, Digital Pathology Market Report.

Digital Pathology Market: Report Scope

Report NameDigital Pathology Market by Product (Software & Analytics, Scanners, Storage & Communication Systems, Services), by Application (Cancer Diagnosis, Drug Discovery & Development, Disease Research, Others (Education and training, clinical diagnostics for non-cancer disease, and veterinary/forensic pathology)), by End User (Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Academic & Research Institutes), by Deployment (On-Premise, Cloud-Based, Hybrid), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
Market Size in 2025USD 1,378.5 Mn (2025)
Market Forecast in 2035USD 4,175.6 Mn (2035)
Growth Rate (CAGR)11.72%
Historical Data Period2023–2025
Base Year2025
Forecast Period2026–2035
Number of Pages300+
Tables & Figures96 tables & 70 figures
Report CodeVMI-1-3-37694
Report FormatPDF
Delivery FormatPDF via email delivery and online download portal
Published DateNovember 2026
Research MethodologyPrimary interviews + secondary research + verified market sizing (top-down and bottom-up triangulation)
Key Companies CoveredLeica Biosystems (Danaher), Roche Diagnostics, Philips, Hamamatsu Photonics, Agilent Technologies, PathAI, Tempus AI (Paige), Proscia, Sectra, Ibex Medical Analytics, Aiforia Technologies, Visiopharm (Grundium), Indica Labs, OptraSCAN
Segments CoveredProduct, Application, End User, Deployment
Regions CoveredNorth America, Europe, Asia Pacific, Latin America, The Middle East, Africa
Customization ScopeUp to 10% free customization: additional country splits, extra company profiles, or deeper sub-segment cuts (for example scanner throughput class or AI algorithm category) on request

What Sets This Digital Pathology Market Report Apart?

Decision-makers comparing market intelligence reports on Digital Pathology will find the VMI report differentiated on the following dimensions.

DimensionVMI ReportIndustry Average
Report Pages300+~120 pages
Forecast Horizon10 years7 years
Segmentation Dims4 dims4-5 dimensions
Historical Data3 years4-5 years
Country Coverage35+ countries15-18 countries
Companies Profiled14 companies10-12 companies
DROC FrameworkFull (4 elem)Drivers only

For custom scope — additional segments, specific geographies, or extended forecast periods — contact sales@vectomatinsights.com

Digital Pathology Market Growth Drivers

Pathologist Shortages and Remote Sign-Out — The microscope has become a capacity bottleneck. In Labcorp's 2026 Pulse of the Pathologist survey of 148 U.S. pathologists, more than 90% said cancer rates are rising and 59% named digital pathology the most impactful response to workforce shortages, while 49% pointed to remote slide reading. Digital slides let a lab route a case to any qualified pathologist at any site on the day it is scanned, which is why Source BioScience is building a telepathology service for more than 85 NHS trusts and clinics on Sectra's Image Exchange Portal. Hospitals & Diagnostic Labs, the end user most exposed to this pressure, already account for 50.0% of 2025 revenue and grow at a 15.14% CAGR, faster than any other end user. The effect is strongest in North America and Europe, where subspecialty expertise is concentrated in a handful of academic centres. MedStar Health's April 2026 deployment of PathAI's AISight Dx across a laboratory network serving more than 40 pathologists is the working template.

FDA-Cleared, End-to-End Clinical Systems — Clinical buyers want one validated route from slide to sign-out, and 2026 delivered it. In August 2026 Leica Biosystems received FDA 510(k) clearance for Aperio iQC DX, AI software that flags six common slide artifacts while slides are still on the scanner, together with the new Aperio GT 180 DX and an enhanced GT 450 DX. In a Heidelberg University study, the software caught up to 24% more artifacts than histotechnicians and cut hands-on review time by 69%. Hamamatsu Photonics followed in September 2026 with clearances for its NanoZoomer S20MD and S540MD scanners, and OptraSCAN won clearance in July 2026 for an integrated scanner with HER2 analysis. Each clearance reduces the validation work a hospital must carry on its own. In structural terms, U.S. digital pathology is moving from a lab-assembled workflow to a regulated, vendor-validated medical-device system.

Consolidation Bringing AI Inside Large Diagnostics Vendors — Capital is flowing to whoever owns the installed base. Roche's May 2026 agreement to acquire PathAI, worth up to USD 1.05 Bn, folds the AISight image management system and a companion-diagnostic algorithm pipeline into Roche Diagnostics' global sales channel. Agilent agreed in October 2026 to pay USD 240 Mn upfront, plus up to USD 30 Mn in milestones, for Proscia, whose platform serves more than 4,000 laboratories, hospitals and clinics, and closed the deal early in its fiscal 2027. Grundium's May 2026 purchase of Visiopharm and Tempus AI's 2025 acquisition of Paige complete a run in which most scaled independent pathology software assets changed hands within twelve months. For buyers, that means fewer integration seams and larger balance sheets behind multi-year contracts. Expect the acquirers to bundle AI with scanners, stains and service in hospital tenders from 2027 onward.

Time is the new currency in pathology.

— Naveen Chandra, Vice President and General Manager, Digital Pathology, Leica Biosystems · Press · Leica Biosystems press release, 24 Mar 2026 [source]

Digital pathology has the potential to improve precision diagnosis of cancer.

— Matt Sause, Chief Executive Officer, Roche Diagnostics, Roche · Press · Roche media release, 7 May 2026 [source]

Digital Pathology Market Challenges to Growth

High Capital Cost and Missing Reimbursement — The business case still rests on productivity, not payment. Labcorp's 2026 survey found that 57% of U.S. pathologists see capital expense as a barrier and 66% worry about paying for AI with no corresponding reimbursement. The AMA has created 43 CPT Category III codes for slide digitisation since 2023, but none carries a national Medicare payment rate, so most U.S. labs fund scanners, storage and software from operating budgets. Community hospitals feel this most, which partly explains why research-funded Pharma & Biotech Companies digitised first. The gap is widest in the United States, and in Latin America and Africa, where import duties add to hardware prices. Until a Category I code arrives, roughly two in three U.S. pathologists will keep treating AI as a cost line rather than a revenue line.

Data Storage and IT Infrastructure Burden — Storage is the hidden line item that stalls projects. A lab scanning several hundred thousand slides a year accumulates petabytes of images it must keep for years, plus the bandwidth to serve them to remote readers without lag. That load lands on hospital IT teams that already run radiology PACS and electronic health records, and on-premise expansions often take longer to approve than the scanners themselves. Storage & Communication Systems is consequently the fastest-growing product category in this report, rising from USD 193.0 Mn in 2025 to USD 960.5 Mn by 2035. The restraint bites hardest in mid-sized hospitals in Europe and North America without a hyperscale cloud agreement. Mount Sinai Health System's pathology leadership calls Philips' AWS-hosted IntelliSite deployment an important next step for scaling across its sites.

A cloud-enabled deployment reduces reliance on on-premise infrastructure.

— Carlos Cordon-Cardo, MD, PhD, Chair, Department of Pathology, Molecular and Cell-Based Medicine, Mount Sinai Health System · Press · Philips press release, Mar 2026 [source]

Digital Pathology Market Growth Opportunities

Cloud and Hybrid Image Archives — The archive is moving off the hospital floor. Hybrid deployment is the fastest-growing model in this report at an 18.0% CAGR, and cloud-based revenue rises from USD 523.8 Mn in 2025 to USD 1,765.9 Mn by 2035, overtaking on-premise. Philips' March 2026 launch of IntelliSite on AWS-hosted HealthSuite and Proscia's August 2026 FDA clearance covering cloud deployment both remove a common procurement objection. For vendors, cloud contracts convert one-off storage sales into recurring revenue tied to slide volume. Structurally, this turns digital pathology storage from a capital asset into a utility bill.

Companion Diagnostics and Pharma Biomarker Algorithms — Pharma is becoming an algorithm customer, not just a scanner customer. Drug Discovery & Development applications grow from USD 358.4 Mn in 2025 to USD 1,343.6 Mn by 2035, passing Cancer Diagnosis in absolute value. Roche's planned PathAI acquisition builds on a 2024 expansion of their partnership into AI-enabled companion-diagnostic algorithms, and Ibex Medical Analytics extended its platform into early biomarker development in January 2026. Proscia already counts 16 of the top 20 pharmaceutical companies as customers. Expect cleared AI scoring of IHC biomarkers for antibody-drug conjugates to become a standard part of oncology drug launches over the next five years.

Asia Pacific and Emerging-Market Telepathology — Growth is shifting east and south. South Korea's market grows at a 13.9% CAGR and Japan's at 12.0%, both ahead of the United States at 10.5%, supported by local AI developers and hospital capacity expansion. In Brazil, PathAI's cooperation with A.C. Camargo Cancer Center aims to extend AI-assisted digital pathology through the public SUS system. Compact, lower-cost scanners, including Grundium's Ocus range and OptraSCAN's OS-Ultra, fit labs without dedicated IT teams. South Korea alone grows from USD 66.6 Mn in 2025 to about USD 244.7 Mn by 2035.

Digital Pathology Market: Key Challenges

Interoperability and Vendor Lock-In — Mixing vendors is still harder than it should be. Many scanners write proprietary file formats, and AI algorithms are often validated against one scanner-viewer pairing, so a lab that adds a second scanner brand can trigger fresh validation. Even Philips' new cloud IntelliSite offering launched with AI interoperability limited at first to a single partner, Ibex. Proscia's August 2026 clearance, with a predetermined change control plan to add new FDA-cleared scanners, image formats and displays without new 510(k) filings, is the clearest answer so far.

Fragmented AI Validation Across Regulators — Regulatory status differs by geography and by use. Ibex Medical Analytics, for example, holds CE-IVD marking and registrations in the U.K., Australia and Brazil, yet only one of its solutions is FDA cleared, with the rest research-use-only in the U.S. Paige's PanCancer Detect and prostate tools reached Leica's Aperio AI Store in September 2026 as research-use products. This split shapes where revenue lands: European labs can buy clinical AI that U.S. labs can only trial. In effect, the AI layer of digital pathology is a set of national markets sharing one technology.

A predetermined change control plan gives customers confidence that Concentriq AP-Dx stays an interoperable foundation as they add new scanners, image formats and displays.

— Ian Cadieux, Head of Quality and Regulatory, Proscia · Press (paraphrased) · Proscia press release, 6 Aug 2026 [source]
Digital pathology market drivers, restraints, opportunities and challenges | Vectomat Insights
Pathologist shortages, cleared end-to-end systems and AI consolidation drive the market, while capital cost and storage load restrain it. Source: Vectomat Insights, Digital Pathology Market Report.

AI's Impact on the Digital Pathology Market

Tempus AI's Paige PanCancer Detect, added to Leica's Aperio AI Store in September 2026, flags suspicious tissue across more than 40 cancer types using a single pathology foundation model, a step beyond the one-organ algorithms that dominated the first wave. AI is also moving upstream into slide quality: Leica's FDA-cleared Aperio iQC DX checks for six artifact types before a slide ever reaches the pathologist.

For labs, this changes the buying decision from individual algorithms to platforms that can host many models and route each case to the right one. It also shifts AI cost from per-test fees toward enterprise licences. Through the 2026–2035 forecast period, expect foundation models to make AI screening routine for most cancer biopsies, with pathologists reviewing flagged regions rather than whole slides.

Digital Pathology Market: Segmentation

The Global Digital Pathology market is segmented by Product, Application, End User, Deployment.

By Product

Leica Biosystems' Aperio GT 450 DX, which won an enhanced FDA 510(k) clearance in August 2026 alongside the new GT 180 DX, shows where the hardware race is heading: faster scanners feeding software that does the analytical work. Software & Analytics is the dominant product category at 42.0% of 2025 revenue (USD 579.0 Mn), because image management, viewer and AI licences renew every year across an installed scanner base. Scanners follow at 34.0% (USD 468.7 Mn) and compound faster, at 13.89% a year. Storage & Communication Systems is the fastest-growing category at a 17.41% CAGR, rising from USD 193.0 Mn to USD 960.5 Mn by 2035, since each scanned slide adds a gigabyte-scale file to the archive. Services revenue slipped from USD 171.0 Mn in 2023 to USD 137.8 Mn in 2025 as vendors folded implementation into platform contracts.

Product-Wise Revenue Breakdown for the Digital Pathology Market, 2023–2025 (USD Million)

Sub-Segment2023 (USD Mn)2024 (USD Mn)2025 (USD Mn)
Software & Analytics481.6541.6579.0
Scanners327.5383.3468.7
Storage & Communication Systems116.7142.5193.0
Services171.0165.0137.8
Digital pathology market share by product — Software & Analytics 42.0% in 2025 | Vectomat Insights
Software & Analytics accounts for 42.0% of 2025 Digital Pathology revenue, ahead of Scanners at 34.0%. Source: Vectomat Insights, Digital Pathology Market Report.

By Application

Aiforia's April 2026 selection as sole AI partner for AP-HP's PROSTIA prostate cancer project, expanding from two to seven Paris hospitals, captures why oncology leads. Cancer Diagnosis holds 46.0% of 2025 revenue (USD 634.1 Mn), anchored by high-volume prostate, breast and colorectal biopsies where cleared algorithms are most mature. Drug Discovery & Development is second at 26.0% (USD 358.4 Mn) and grows at 14.13% a year, overtaking cancer diagnosis in absolute value by 2035 (USD 1,343.6 Mn against USD 1,258.5 Mn). Disease Research is the fastest-growing application at a 17.64% CAGR, reaching USD 1,120.1 Mn by 2035 despite a dip to USD 220.6 Mn in 2025, as academic consortia digitise tissue archives for AI training. The Others category, covering education, non-cancer clinical diagnostics and veterinary and forensic pathology, holds 12.0%.

Application-Wise Revenue Breakdown for the Digital Pathology Market, 2023–2025 (USD Million)

Sub-Segment2023 (USD Mn)2024 (USD Mn)2025 (USD Mn)
Cancer Diagnosis463.4529.1634.1
Drug Discovery & Development290.5321.0358.4
Disease Research221.9238.5220.6
Others (Education and training, clinical diagnostics for non-cancer disease, and veterinary/forensic pathology)121.0143.8165.4

By End User

MedStar Health's April 2026 decision to deploy PathAI's AISight Dx across its laboratory network, serving more than 40 pathologists, is typical of where demand is concentrating. Hospitals & Diagnostic Labs are the dominant end user at 50.0% of 2025 revenue (USD 689.2 Mn) and also the fastest-growing, at a 15.14% CAGR to USD 2,821.6 Mn by 2035, because primary diagnosis, remote sign-out and second opinions all sit in clinical labs. Pharma & Biotech Companies hold 30.0% (USD 413.6 Mn) but grow at only 4.59% a year; they adopted slide scanning early for research and toxicology, so their base is already digital. Academic & Research Institutes account for 20.0% (USD 275.7 Mn) and expand at 9.86% annually, helped by national tissue-data programmes such as the UK's National Pathology Imaging Co-operative.

End User-Wise Revenue Breakdown for the Digital Pathology Market, 2023–2025 (USD Million)

Sub-Segment2023 (USD Mn)2024 (USD Mn)2025 (USD Mn)
Hospitals & Diagnostic Labs464.3570.4689.2
Pharma & Biotech Companies389.5403.4413.6
Academic & Research Institutes243.0258.6275.7
Digital pathology market share by end user — Hospitals & Diagnostic Labs 50.0% in 2025 | Vectomat Insights
Hospitals & Diagnostic Labs account for half of 2025 Digital Pathology revenue and are the fastest-growing end user. Source: Vectomat Insights, Digital Pathology Market Report.

By Deployment

Philips moved its IntelliSite Pathology Solution onto AWS-hosted HealthSuite in March 2026, and Mount Sinai Health System is among the early adopters of that model. On-Premise remains the dominant deployment at 47.8% of 2025 revenue (USD 658.5 Mn), since most installed scanners still write to hospital-owned servers behind the firewall. Its revenue barely moved between 2024 and 2025, though. Hybrid is the fastest-growing model at an 18.0% CAGR, rising from USD 196.2 Mn to USD 1,027.0 Mn by 2035, as labs keep recent cases local and push older slides to cloud archives. Cloud-Based deployment holds 38.0% (USD 523.8 Mn), grows at 12.92% a year and overtakes on-premise revenue before 2035 (USD 1,765.9 Mn against USD 1,382.7 Mn).

Deployment-Wise Revenue Breakdown for the Digital Pathology Market, 2023–2025 (USD Million)

Sub-Segment2023 (USD Mn)2024 (USD Mn)2025 (USD Mn)
On-Premise654.0677.3658.5
Cloud-Based319.6393.8523.8
Hybrid123.2161.3196.2
Digital pathology market segmentation — Software & Analytics leads product revenue at 42.0% | Vectomat Insights
Software & Analytics, Cancer Diagnosis, Hospitals & Diagnostic Labs and On-Premise deployment lead their dimensions in 2025. Source: Vectomat Insights, Digital Pathology Market Report.

Digital Pathology Market: Production & Volume Analysis, 2025

This section counts active site deployments: an installed scanner, a licensed software platform, a storage or communication installation, or a service contract running at one laboratory site. VMI estimates 18,600 active deployments worldwide in 2025, implying average annual revenue of about USD 74,100 per deployment. Software & Analytics leads on both volume (47.0% of units) and value (42.0%), but Scanners show the sharpest volume-value split, at 20.5% of units against 34.0% of revenue, because clinical-grade scanners carry six-figure prices.

Metric2025 Volume (active site deployments)Share of Units
Total active site deployments (2025)18,600100.0%
Software & Analytics8,74247.0%
Scanners3,81320.5%
Storage & Communication Systems3,34818.0%
Services2,69714.5%

Reference point: Visiopharm — Reported more than 750 customer accounts in over 40 countries and nine IVDR-cleared diagnostic algorithms when Grundium agreed to acquire it (May 2026). 750+ customer accounts in 40+ countries.

Digital Pathology Market: Competitive Landscape

Roche's agreed purchase of PathAI for up to USD 1.05 Bn in May 2026 reset the competitive map, turning an AI partner into an in-house capability. Hardware is moderately concentrated among Leica Biosystems, Philips, Hamamatsu Photonics and Roche; software and AI remain fragmented. Agilent's completed purchase of Proscia, agreed in October 2026, and Grundium's purchase of Visiopharm show scanner and staining vendors buying software to defend their installed base. Independent AI developers such as Ibex Medical Analytics, Aiforia Technologies and Tempus AI's Paige unit increasingly sell through scanner partners, while Sectra and Indica Labs compete on image management. Key players include Leica Biosystems (Danaher), Roche Diagnostics, Philips, Hamamatsu Photonics, Agilent Technologies, PathAI, Tempus AI (Paige), Proscia, Sectra, Ibex Medical Analytics, Aiforia Technologies, Visiopharm (Grundium), Indica Labs, OptraSCAN, among others.

CompanyHQ CountryPrimary FocusKey StrategyNotable Recent Action
Leica Biosystems (Danaher)GermanyWhole-slide scanners (Aperio GT 450 DX, GT 180 DX) and image managementComplete cleared system plus open AI app storeWon FDA 510(k) clearances for Aperio iQC DX AI quality control, the new GT 180 DX and an enhanced GT 450 DX in August 2026
Roche DiagnosticsSwitzerlandnavify Digital Pathology, VENTANA DP scanners and companion-diagnostic algorithmsAcquisition-led AI and companion-diagnostic build-outAgreed in May 2026 to acquire PathAI for up to USD 1.05 Bn, with closing expected in the second half of 2026
PhilipsNetherlandsIntelliSite Pathology Solution (scanner, image management, AI integration)Cloud delivery through HealthSuiteLaunched the cloud-enabled IntelliSite Pathology Solution on HealthSuite, hosted on AWS, in the U.S. and Canada in March 2026
Hamamatsu PhotonicsJapanNanoZoomer MD slide scanners, OEM supply to partnersBroad cleared scanner range and OEM partnershipsReceived FDA 510(k) clearance for the NanoZoomer S20MD and S540MD scanners in September 2026
Agilent TechnologiesU.S.S540MD slide scanner (Hamamatsu OEM) and pathology staining workflowPairing staining chemistry with scanners and softwareAgreed in October 2026 to acquire Proscia for USD 240 Mn upfront plus up to USD 30 Mn in milestones, and completed the purchase early in its fiscal 2027
PathAIU.S.AISight Dx image management and AI algorithms for diagnosis and drug developmentHealth-system platform deals plus biopharma servicesSigned an April 2026 partnership to deploy AISight Dx across MedStar Health's laboratory network, then agreed to be acquired by Roche in May 2026
Tempus AI (Paige)U.S.Paige Prostate, Paige PanCancer Detect and pathology foundation modelsFoundation-model AI distributed through scanner partnersBrought Paige PanCancer Detect and Paige Prostate to the Leica Aperio AI Store in September 2026, after acquiring Paige for USD 81.25 Mn in August 2025
ProsciaU.S.Concentriq image management platform for clinical labs and pharmaScanner-agnostic, cloud-ready platform with a PCCPReceived FDA 510(k) clearance for Concentriq AP-Dx with a predetermined change control plan in August 2026, then joined Agilent through an acquisition agreed in October 2026
SectraSwedenEnterprise imaging and digital pathology PACS, Image Exchange PortalRegional and national network dealsSigned a three-year agreement with Source BioScience in September 2026 to route NHS pathology cases via its Image Exchange Portal
Ibex Medical AnalyticsIsraelAI cancer detection and grading (Galen platform)Clinical lab-network deployments plus biopharma expansionAppointed Yair Heller as CEO in February 2026 and announced new U.S. deployments with PathGroup and HNL Lab Medicine
Aiforia TechnologiesFinlandCloud AI image analysis for clinical and research pathologyHospital-group contracts in EuropeSelected in April 2026 as sole AI partner for AP-HP's PROSTIA prostate cancer project, expanding from two to seven hospitals
Visiopharm (Grundium)DenmarkAI precision pathology and biomarker quantification softwareIntegration with Grundium scanners into one platformAgreed to be acquired by Finnish scanner maker Grundium in May 2026, bringing 750+ customer accounts in 40+ countries
Indica LabsU.S.HALO image analysis and HALO AP image managementClinical co-commercialisation with Leica BiosystemsUnveiled an AI-powered companion diagnostics offering built on its HALO platform in May 2026, ahead of ASCO 2026
OptraSCANU.S.OS-Ultra whole-slide scanners and ImagePath software with HER2 analysisIntegrated, lower-cost scanner systemsReceived FDA 510(k) clearance (K260755) for the integrated OptraSCAN System with HER2 image analysis in July 2026

Strategic activity is converging on three themes. First, consolidation: Roche-PathAI, Agilent-Proscia and Grundium-Visiopharm all pair hardware or chemistry with software in 2026. Second, regulatory scope as a moat, with Leica's AI quality-control clearance and Proscia's change control plan widening what a single cleared system covers. Third, distribution through app stores, as Tempus' Paige tools now ship inside Leica's Aperio AI Store. Expect independent AI vendors to keep choosing a scanner partner or a buyer.

Digital pathology competitive positioning — 14 companies by installed base and workflow coverage | Vectomat Insights
Leica Biosystems, Roche Diagnostics and Philips combine broad clinical installed bases with end-to-end workflow coverage. Source: Vectomat Insights, Digital Pathology Market Report.

Digital Pathology Market: Value Chain Overview

Slide Preparation & Scanning Hardware — Labs stain and mount tissue slides, then whole-slide scanners digitise them at 20x or 40x magnification. Scanner throughput, focus quality and artifact rates decide how fast a lab can go fully digital, which is why AI-assisted quality control, such as Leica's FDA-cleared Aperio iQC DX, now sits at this stage. Staining chemistry suppliers are moving closer to scanning as well. Key Players: Leica Biosystems, Hamamatsu Photonics, Philips, Roche Diagnostics, Agilent Technologies, OptraSCAN.

Image Management, Storage & Communication — Image management systems index each slide, link it to the laboratory information system and serve it to pathologists in a viewer, while storage and network layers hold gigabyte-scale files for years. This is the stage moving fastest to cloud and hybrid models, and where interoperability standards such as DICOM matter most. Key Players: Sectra, Proscia, Roche Diagnostics (navify Digital Pathology), Philips, Indica Labs.

AI Analysis & Clinical Reporting — AI algorithms screen, grade and quantify disease on the images, flagging suspicious regions or scoring biomarkers before the pathologist signs out a report. Most clinical revenue here comes from prostate, breast and gastrointestinal cancer tools, with companion-diagnostic algorithms for pharma the next growth pool. Hospitals and reference labs are the buyers. Key Players: PathAI, Ibex Medical Analytics, Tempus AI (Paige), Aiforia Technologies, Visiopharm.

Digital Pathology Market: Regional Analysis

North America leads the Global Digital Pathology market with a 40.0% share and Asia Pacific is the fastest-growing region, a split that reflects where FDA-cleared clinical workflows already exist versus where pathologist shortages and new hospital capacity are pulling adoption forward.

North America Digital Pathology Market

MedStar Health signed with PathAI in April 2026 and PathGroup went live with Ibex Medical Analytics earlier in the year, so large U.S. lab networks are no longer piloting. North America holds 40.0% of the 2025 Digital Pathology market (USD 551.4 Mn), with the United States contributing USD 452.1 Mn and forecast to grow at a 10.5% CAGR to about USD 1,227.0 Mn by 2035. A deep stack of FDA clearances, from Leica's Aperio GT 450 DX to Hamamatsu's NanoZoomer S540MD, gives labs a cleared route to primary diagnosis. Reimbursement is the main brake, since none of the 43 CPT Category III digitisation codes carries a national payment rate. Proscia's August 2026 clearance, covering cloud hosting and future scanners under one change control plan, shows how vendors are routing around that friction.

United States Digital Pathology Market Snapshot

MetricValue
Market Size (2025)USD 452.1 Mn
Forecast Value (2035)USD 1,227.0 Mn
CAGR (2026–2035)10.5%
United States digital pathology market — USD 452.1 Mn (2025) to USD 1,227.0 Mn (2035) | Vectomat Insights
The United States Digital Pathology market grows from USD 452.1 Mn in 2025 to USD 1,227.0 Mn by 2035 at a 10.5% CAGR. Source: Vectomat Insights, Digital Pathology Market Report.

Europe Digital Pathology Market

Source BioScience's September 2026 contract with Sectra, routing up to 60,000 NHS cases in its first year to external pathologists, shows how Europe is digitising: through networks rather than single sites. Europe holds 26.14% of the 2025 market (USD 360.3 Mn). Germany is the largest country market at USD 96.8 Mn and grows at a 10.1% CAGR to about USD 253.4 Mn by 2035, while the U.K., France and the Nordics are the most advanced adopters, backed by NHS funding for the National Pathology Imaging Co-operative and France 2030 money for AP-HP's PROSTIA project. IVDR is the main hurdle, stretching certification timelines for AI algorithms. Structurally, Europe is a market of shared regional platforms, where one procurement can convert dozens of hospitals at once.

Germany Digital Pathology Market Snapshot

MetricValue
Market Size (2025)USD 96.8 Mn
Forecast Value (2035)USD 253.4 Mn
CAGR (2026–2035)10.1%
Germany digital pathology market — USD 96.8 Mn (2025) to USD 253.4 Mn (2035) | Vectomat Insights
The Germany Digital Pathology market grows from USD 96.8 Mn in 2025 to USD 253.4 Mn by 2035 at a 10.1% CAGR. Source: Vectomat Insights, Digital Pathology Market Report.

Asia Pacific Digital Pathology Market

Hamamatsu Photonics won FDA 510(k) clearance for its NanoZoomer S20MD and S540MD scanners in September 2026, a reminder that much of the world's slide-scanning hardware is designed in Asia Pacific. The region holds 23.0% of 2025 revenue (USD 317.1 Mn) and is the fastest-growing region. South Korea leads the growth story at USD 66.6 Mn in 2025 and a 13.9% CAGR, reaching about USD 244.7 Mn by 2035, helped by home-grown AI developers such as Lunit. Japan, at USD 92.0 Mn and a 12.0% CAGR, is the larger market today, while China and India add hospital-led volume. The principal challenge is uneven reimbursement and a thin pathologist workforce outside major cities. Expect Asia Pacific to keep closing the gap with Europe through 2035.

South Korea Digital Pathology Market Snapshot

MetricValue
Market Size (2025)USD 66.6 Mn
Forecast Value (2035)USD 244.7 Mn
CAGR (2026–2035)13.9%
South Korea digital pathology market — USD 66.6 Mn (2025) to USD 244.7 Mn (2035) | Vectomat Insights
The South Korea Digital Pathology market grows from USD 66.6 Mn in 2025 to USD 244.7 Mn by 2035 at a 13.9% CAGR. Source: Vectomat Insights, Digital Pathology Market Report.

Latin America Digital Pathology Market

PathAI's cooperation with A.C. Camargo Cancer Center to extend AI-assisted digital pathology through Brazil's public SUS network is the region's clearest anchor. Latin America holds 5.0% of 2025 revenue (USD 68.9 Mn), led by Brazil, with private reference labs in São Paulo, Bogotá and Santiago making most of the purchases. Telepathology links between capital-city specialists and provincial hospitals are the most practical use case. The principal challenge is capital: scanner and storage budgets compete with basic laboratory capacity, and import duties add to hardware prices. At 5.0% of global revenue, the region still accounts for roughly one dollar in every twenty spent on digital pathology.

The Middle East Digital Pathology Market

Israel is the region's technology anchor as home to Ibex Medical Analytics, whose AI cancer-detection platform now runs in clinical labs in Europe and the United States. The Middle East holds 3.05% of 2025 revenue (USD 42.1 Mn). Saudi Arabia and the UAE are buying scanners and image-management systems as part of national digital-health programmes and new oncology centres, and Turkey adds volume through its large public hospitals. The main challenge is a shortage of subspecialty pathologists, which telepathology is meant to ease but which also slows local validation. Leica Biosystems' June 2026 launch of its AI-powered digital pathology solution for European and Middle Eastern labs gives Gulf buyers a single-vendor route to clinical use.

Africa Digital Pathology Market

South Africa's private pathology networks and Egypt's large university hospitals are the continent's early adopters, using scanners mainly to send cases to specialists elsewhere. Africa holds 2.81% of 2025 revenue (USD 38.8 Mn), led by South Africa and Egypt, with Nigeria the largest untapped market. Compact, lower-cost scanners such as Grundium's Ocus range suit labs without dedicated IT teams. The principal challenge is connectivity: whole-slide images are large, and limited bandwidth outside major cities makes uploads slow and expensive. Structurally, African digital pathology is a telepathology market first and an AI market second.

Digital pathology market share by region — North America leads with 40.0% in 2025 | Vectomat Insights
North America holds 40.0% of the 2025 Digital Pathology market, and Asia Pacific is the fastest-growing region. Source: Vectomat Insights, Digital Pathology Market Report.
Digital pathology product mix by region — North America, Europe, Asia Pacific | Vectomat Insights
Software & Analytics takes the largest product share in all three leading regions, while Asia Pacific spends proportionally more on scanners. Source: Vectomat Insights, Digital Pathology Market Report.

Full Country Coverage

RegionCountries Covered
North AmericaThe U.S., Canada, Mexico
EuropeGermany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe
Asia PacificChina, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific
Latin AmericaBrazil, Argentina, Colombia, Chile, Peru, Rest of Latin America
The Middle EastGCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East
AfricaSouth Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa

Note: Country-level market sizing, historical data, and forecasts available for all geographies listed. Custom regional add-ons available — contact sales@vectomatinsights.com

Policy and Government Support Shaping the Digital Pathology Market

Public data and AI infrastructure programme — In October 2024 the UK government awarded GBP 5.1 Mn through the NHS Data for Research and Development Programme to the National Pathology Imaging Co-operative at Leeds Teaching Hospitals, to build a national digital pathology platform and share NHS slide data for AI development. (NHS Data for Research and Development Programme (National Pathology Imaging Co-operative))

Regulatory-approval programme — The FDA's December 2024 final guidance on predetermined change control plans for AI-enabled device software lets vendors pre-authorise future updates; Proscia's August 2026 Concentriq AP-Dx clearance used it to cover new scanners, image formats and displays without fresh 510(k) filings. (FDA Predetermined Change Control Plan (PCCP) guidance for AI-enabled device software functions)

Public funding for clinical AI deployment — France 2030, operated by Bpifrance, is funding AP-HP's two-year PROSTIA project, which brings AI-assisted prostate cancer diagnosis into routine use across seven Paris public hospitals. (France 2030 (Bpifrance) PROSTIA project)

Reimbursement and coding framework — The AMA added 13 CPT Category III slide-digitisation codes in 2023 and 30 more in 2024, giving U.S. labs a way to report digital work, although CMS has not yet assigned national payment rates to any of them. (AMA CPT Category III digital pathology codes (0751T-0763T and 2024 additions))

Recent Developments in the Digital Pathology Market

Recent activity is dominated by consolidation and clearances: three acquisitions put independent pathology software inside larger diagnostics groups, while FDA decisions widened what a single cleared system can cover.

DateCompanyTypeDescriptionMarket Impact
Oct 2026Agilent TechnologiesM&AAgreed to acquire digital pathology software provider Proscia for USD 240 Mn upfront plus up to USD 30 Mn in milestone payments, and completed the purchase early in Agilent's fiscal 2027. [source]Adds a scanner-agnostic image management platform used by 4,000+ labs, hospitals and clinics to Agilent's staining and scanner business.
Sep 2026Leica Biosystems / Tempus AIPartnershipLeica Biosystems added Tempus' Paige PanCancer Detect and Paige Prostate suite to its Aperio AI Store for research use. [source]Puts foundation-model AI covering 40+ cancer types in front of Leica's installed scanner base through an app-store channel.
Aug 2026Leica BiosystemsRegulatoryReceived FDA 510(k) clearance for Aperio iQC DX AI quality-control software, the new Aperio GT 180 DX scanner and an enhanced Aperio GT 450 DX. [source]Extends cleared clinical scope from scanning to automated slide-quality checks and gives mid-volume labs a cleared entry scanner.
May 2026RocheM&AEntered a definitive merger agreement to acquire PathAI in a deal worth up to USD 1.05 Bn, with closing expected in the second half of 2026. [source]Brings the AISight image management system and AI companion-diagnostic algorithms inside Roche Diagnostics.
May 2026GrundiumM&AAgreed to acquire Danish AI precision pathology software developer Visiopharm, which has 750+ customer accounts in 40+ countries. [source]Combines compact scanners with biomarker analysis software in one platform, mainly serving European labs.
Mar 2026PhilipsProduct LaunchLaunched the cloud-enabled Philips IntelliSite Pathology Solution on HealthSuite, hosted on Amazon Web Services, in the U.S. and Canada. [source]Lowers the on-premise infrastructure barrier for health systems scaling digital pathology across sites.

Research Methodology

Overall approach

VMI sized the Digital Pathology market bottom-up and top-down. The bottom-up model counts scanner placements, software and AI licences, storage installations and service contracts by end user and region, priced from vendor disclosures and tender data; the top-down model reconciles that build against reported digital pathology revenue at Leica Biosystems, Roche, Philips, Hamamatsu and listed AI vendors such as Aiforia. Base-year 2025 values, regional splits and segment tables come from the VMI Data Tracker, VMI's proprietary market database.

Primary research

Primary inputs came from interviews with laboratory medical directors, histology managers and hospital IT leads at digitised and partially digitised labs, scanner and image-management vendor product managers, and AI developers selling into clinical and pharma accounts. Interviews focused on scanner throughput per site, archive growth per slide, AI licence pricing models and the share of cases signed out digitally.

Secondary research

Secondary research drew on FDA 510(k) databases, CE-IVD and IVDR certificates, company annual reports and investor materials, press releases on 2025–2026 clearances and acquisitions, Labcorp's 2026 Pulse of the Pathologist survey, Digital Pathology Association reimbursement guidance on CPT Category III codes, NHS and France 2030 programme announcements, and IARC GLOBOCAN 2022 cancer incidence data.

Data validation

Segment, regional and country values were triangulated against each other so every segment table sums to the 2023, 2024 and 2025 market totals, and every country value sits inside its regional total. Volume estimates were checked against vendor-disclosed installed bases, such as Visiopharm's 750+ customer accounts, and the implied revenue per deployment was compared with scanner and licence price points. Company-level figures were cross-checked against reported revenue at listed vendors including Danaher, Roche, Philips, Hamamatsu Photonics and Agilent.

Read the full VMI market sizing & forecasting methodology →

Market Coverage Definitions

How this report defines the scope of the Digital Pathology Market: what each segment and sub-segment includes.

SegmentMarket Coverage Definition
By ProductSegments the market by the type of digital pathology offering, covering software and analytics, scanners, storage and communication systems, and services.
By ApplicationSegments the market by the clinical or research use of digital pathology, covering cancer diagnosis, drug discovery and development, disease research, and other applications.
By End UserSegments the market by the type of organization deploying digital pathology, covering hospitals and diagnostic labs, pharmaceutical and biotech companies, and academic and research institutes.
By DeploymentSegments the market by how digital pathology software and data infrastructure are hosted, covering on-premise, cloud-based, and hybrid deployment.

By Product

Sub-SegmentMarket Coverage Definition
Software & AnalyticsImage management systems, viewers, and AI-based algorithmic analysis software used to store, review, and interpret digitized pathology slides, including software cleared for primary diagnosis use and software intended for research applications.
ScannersWhole slide imaging hardware used to digitize glass pathology slides into high-resolution digital images, ranging from lower-throughput scanners for smaller laboratories to high-capacity scanners designed for large, high-volume laboratories.
Storage & Communication SystemsInfrastructure used to store, archive, and transmit large digital pathology image files between systems and sites, including systems supporting DICOM-based image interoperability standards.
ServicesInstallation, validation, training, and ongoing technical support services associated with deploying and maintaining digital pathology hardware and software.

By Application

Sub-SegmentMarket Coverage Definition
Cancer DiagnosisDigital pathology used to support the diagnosis of cancer from tissue samples, the application with the largest clinical adoption given the central role of pathology review in cancer diagnosis and treatment planning.
Drug Discovery & DevelopmentDigital pathology used by pharmaceutical and biotech companies to support preclinical and clinical drug development, including image-based biomarker identification and companion diagnostic development.
Disease ResearchDigital pathology used in academic and translational research settings to study disease mechanisms and tissue biology beyond direct clinical diagnosis or drug development.
OthersAdditional digital pathology applications, including education, quality assurance, and remote consultation use cases.

By End User

Sub-SegmentMarket Coverage Definition
Hospitals & Diagnostic LabsHospital pathology departments and independent diagnostic laboratories that use digital pathology for routine clinical case review and diagnosis, the largest end-user group given the volume of pathology cases processed in clinical settings.
Pharma & Biotech CompaniesPharmaceutical and biotechnology companies using digital pathology in drug discovery, preclinical research, and clinical trial support, including biomarker and companion diagnostic development.
Academic & Research InstitutesUniversities and research institutions using digital pathology for disease research, pathology education, and early-stage technology development.

By Deployment

Sub-SegmentMarket Coverage Definition
On-PremiseDigital pathology software and image storage infrastructure hosted on servers located within a laboratory or hospital's own facility, historically the most common deployment model given large image file sizes and data governance requirements.
Cloud-BasedDigital pathology software and image storage hosted on external cloud infrastructure, offering easier scalability and remote access, an increasingly common deployment model as cloud providers address healthcare data security and compliance requirements.
HybridA combination of on-premise and cloud-based infrastructure, often used to keep sensitive patient data on local servers while using cloud resources for computationally intensive AI analysis or for data sharing across multiple sites.

Market Assessment Framework

The four-step framework used to size and validate the Digital Pathology market.

  1. 1

    Bottom-Up Approach

    Market value is built up from individually identified digital pathology products across software and analytics, scanners, storage and communication systems, and services, starting with commercially available and recently cleared offerings. Revenue for each product is estimated from installed scanner base, software licensing or subscription fees, and service revenue, then aggregated upward to the product, application, and total market level.

  2. 2

    Volume-Based Assessment

    Scanner installation and slide digitization volumes are estimated separately for hospital and diagnostic laboratory deployments and for pharmaceutical and biotech research use, since the two buyer groups adopt digital pathology at different paces and for different purposes. Laboratory case volume, digitization rate, and AI algorithm adoption rate are modeled by end user and application rather than applying a single volume assumption across the market.

  3. 3

    Price & Revenue Benchmarking

    Scanner pricing, software licensing fees, and algorithmic analysis reimbursement rates are benchmarked against publicly disclosed pricing for comparable digital pathology products, adjusted for regional reimbursement differences. Benchmarking distinguishes between one-time hardware and software licensing revenue and newer, usage-based algorithmic analysis billing revenue, which follow different growth trajectories.

  4. 4

    Market Validation & Triangulation

    Estimates built from the bottom-up and volume-based approaches are cross-checked against company-reported scanner shipment and software deployment figures, regulatory clearance disclosures, and reimbursement policy changes affecting algorithmic pathology analysis billing. Discrepancies beyond an acceptable range are investigated and reconciled before the estimate is finalized.

Specialized Analyst Insights

Analyst view · VMI Diagnostics & Monitoring research team

Digital pathology has moved from a digitization story to a computation story. For years, the central value proposition was simply converting glass slides into digital images that could be stored, shared, and reviewed remotely. The more consequential shift now underway is payers beginning to recognize algorithmic analysis of those images as a distinct, billable service. New Medicare billing codes covering AI-based prognostic analysis across specific cancer types, separate from the conventional slide interpretation a pathologist performs, are an early but meaningful signal that the economics of this market are starting to reward the software layer, not just the imaging hardware underneath it.

Large diagnostics companies have chosen acquisition over internal development to gain AI-native pathology capability, mirroring a pattern seen in other software-heavy diagnostic categories. Roche's agreement to acquire PathAI for up to $1.05 billion gives a company with deep existing strength in companion diagnostics and oncology testing a ready-made AI platform rather than years of internal model development. How well that acquired technology integrates with Roche's existing diagnostics and clinical trial support businesses, and whether it can scale globally as promised, will be worth watching as a signal for how other large diagnostics companies approach AI pathology capability.

Hardware consolidation has continued in parallel with the AI dealmaking, and remains relevant even as algorithmic analysis gets more attention. Scanner and imaging workflow companies focused on autonomous, largely unattended slide scanning are being acquired by larger imaging and life sciences companies, reflecting continued demand for reducing the manual laboratory labor involved in digitizing slides at scale, a persistent operational bottleneck given global shortages of trained pathologists and laboratory technicians in many markets.

Foundation models trained across many pathology tasks at once, rather than narrow, single-indication classifiers, represent an emerging second wave of computational pathology development. Unlike a narrowly scoped, cleared product such as a primary diagnosis image management system, broad foundation models trained to handle dozens or more than a hundred distinct clinical tasks face a less defined regulatory and clinical validation pathway, since existing device clearance frameworks were generally built around evaluating a specific, bounded clinical claim rather than a general-purpose model's wide range of potential uses.

Regional Regulations

Regulatory authorities and requirements across 9 jurisdictions
RegionKey Regulatory Authorities / FrameworksGovernment Regulations and Regulatory Considerations
North AmericaU.S.U.S. FDA, CMSWhole slide imaging systems and AI-based pathology image analysis software are generally regulated as Class II medical devices, requiring 510(k) clearance demonstrating substantial equivalence to an existing cleared device. Software intended for primary diagnosis, interpreting a case without a conventional microscope as backup, is treated as a higher-risk use requiring a specific clearance for that purpose. CMS has also begun creating dedicated billing codes for AI-based algorithmic pathology analysis, separate from conventional slide interpretation.
EuropeEuropean Commission, Notified BodiesDigital pathology devices and AI software fall under the EU Medical Device Regulation, and in some cases the In Vitro Diagnostic Regulation depending on the specific diagnostic claim, with CE marking required through a notified body. The EU Artificial Intelligence Act adds additional obligations for medical AI software classified as high-risk, layering on top of existing device regulation.
Asia PacificJapanPMDA, MHLWDigital pathology devices and software are regulated under Japan's Pharmaceuticals and Medical Devices Act, with the SAKIGAKE designation system available to accelerate review of innovative software-based diagnostic aids addressing unmet clinical needs.
Asia PacificChinaNMPADigital pathology scanners and AI diagnostic support software are regulated as Class II or Class III medical devices depending on function, administered by the NMPA, which has been actively approving a growing number of domestically developed AI-based medical devices as part of a broader national push in AI diagnostics.
Asia PacificIndiaCDSCODigital pathology scanners and software fall under India's Medical Device Rules, with software-as-a-medical-device oversight still developing. Telepathology and digital pathology adoption has grown as a way to extend diagnostic access to areas with limited local pathologist availability.
Asia PacificSouth KoreaMFDSDigital pathology devices and AI-based diagnostic software are regulated under South Korea's Medical Device Act, with AI and software-based diagnostic tools reviewed through dedicated approval guidelines for AI medical devices.
Latin AmericaBrazilANVISADigital pathology scanners and software are regulated as medical devices by ANVISA, with import and local registration requirements applying to internationally developed products entering the Brazilian market.
Middle EastNational health product regulatory authorities, GCC frameworksDigital pathology and telepathology adoption has grown as a way to address pathologist shortages across the region, with regulatory frameworks for the underlying devices and software evolving alongside broader national digital health initiatives.
Global / InternationalISO, WHOInternational standards support device and software quality, including ISO 13485 for medical device quality management and IEC 62304 for medical device software, while DICOM standards support image interoperability across different vendors' platforms. The World Health Organization's guidance on AI in health has increasingly referenced computational pathology as an application area for extending diagnostic capacity in lower-resource settings.

Strategic Activities

6 strategic developments shaping the Digital Pathology Market
DateCompany / CompaniesDevelopment TypeDevelopment and Impact on Market
May 2025Danaher (Leica Biosystems), AstraZenecaPartnershipDanaher and AstraZeneca announced a partnership to develop and commercialize new diagnostic tests that identify patients most likely to benefit from precision medicine treatments, with the first products built on digital and computational pathology technology from Danaher's Leica Biosystems unit. The deal paired a major diagnostics and life sciences company with a major pharmaceutical company specifically around AI-assisted pathology algorithms rather than conventional companion diagnostics alone. [source]
Jul 2025PathAIRegulatory ApprovalPathAI received FDA 510(k) clearance for its AISight Dx digital pathology image management system for use in primary diagnosis, when used with specific Hamamatsu and Leica Aperio slide scanners. The clearance included a Predetermined Change Control Plan allowing PathAI to add certain future scanners, displays, and file formats without filing a new 510(k) for each change, a notable regulatory efficiency for a fast-moving software product. [source]
Aug 2025EVIDENT, PramanaAcquisitionEVIDENT agreed to acquire Pramana, a maker of fully autonomous whole slide image scanning systems designed to reduce manual laboratory labor in digitizing pathology slides. The deal reflected continued consolidation in digital pathology hardware even as attention in the broader market increasingly shifted toward AI software, since autonomous scanning workflow remains a real operational bottleneck for laboratories scaling digitization. [source]
May 2026Roche, PathAIAcquisitionRoche agreed to acquire PathAI for up to $1.05 billion, including $750 million upfront and up to $300 million in milestone payments, with the deal expected to close in the second half of 2026. Roche said it planned to combine PathAI's AI pathology tools with its existing oncology diagnostics platforms and scale the technology globally, one of the largest acquisitions to date of an AI-native digital pathology company by an established diagnostics player. [source]
Jul 2026AMA, CMSReimbursement UpdateThe AMA published new Category III CPT codes covering AI-based algorithmic analysis of digital pathology slides for bladder, pancreatic, breast, and prostate cancer, reporting prognostic and treatment-response parameters, with CMS proposing specific payment rates and moving the codes off the standard clinical lab fee schedule. The move created the clearest billing pathway yet for algorithmic pathology analysis as a service distinct from conventional slide interpretation.
Aug 2026Leica BiosystemsRegulatory ApprovalLeica Biosystems received FDA clearance for Aperio iQC DX, described as the first FDA-cleared AI-assisted digital pathology quality control software for clinical use, which automatically flags common slide scanning issues such as air bubbles and out-of-focus areas before a slide leaves the scanner. The company also launched an upgraded high-throughput clinical scanner and a new mid-volume scanner aimed at laboratories without the case volume to justify its largest systems. [source]

Related Analysis

Blog · Diagnostics & Monitoring

Roche Just Paid Over a Billion Dollars to Prove Digital Pathology Is No Longer About Scanning Slides

A billion-dollar acquisition, a new Medicare billing code for AI algorithms, and a quality control tool that catches scanning errors before they happen all point to the same shift: the money in digital pathology has moved from the scanner to the software running on top of it.

Read the article →

Table of Contents: Digital Pathology Market Report

12 chapters · 96 tables & 70 figures. Expand a chapter to see its sub-sections.

Introduction
  1. Report Description and Scope
  2. Market Definition
Research Methodology
  1. Research Approach
  2. Primary and Secondary Research
  3. Data Validation and Triangulation
Executive Summary
  1. Market Snapshot 2025–2035
  2. Key Findings
Market Dynamics
  1. Drivers
  2. Restraints
  3. Opportunities
  4. Challenges
  5. AI's Impact on the Digital Pathology Market
Digital Pathology Market — By Product
  1. Market Size and Share By Product, 2023–2035
  2. Software & Analytics
  3. Scanners
  4. Storage & Communication Systems
  5. Services
  6. Production & Volume Analysis, 2025
Digital Pathology Market — By Application
  1. Market Size and Share By Application, 2023–2035
  2. Cancer Diagnosis
  3. Drug Discovery & Development
  4. Disease Research
  5. Others
Digital Pathology Market — By End User
  1. Market Size and Share By End User, 2023–2035
  2. Hospitals & Diagnostic Labs
  3. Pharma & Biotech Companies
  4. Academic & Research Institutes
Digital Pathology Market — By Deployment
  1. Market Size and Share By Deployment, 2023–2035
  2. On-Premise
  3. Cloud-Based
  4. Hybrid
Regional Analysis
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. The Middle East
  6. Africa
  7. Policy and Government Support
Competitive Landscape
  1. Market Structure and Strategic Themes
  2. Value Chain Overview
  3. Company Profiles
Recent Developments
  1. Mergers and Acquisitions
  2. Regulatory Clearances
  3. Product Launches and Partnerships
Appendix
  1. Related Reports

List of Tables (selected)

  1. Digital Pathology Market Size, 2023–2035 (USD Million)
  2. Product-Wise Revenue Breakdown for the Digital Pathology Market, 2023–2025 (USD Million)
  3. Application-Wise Revenue Breakdown for the Digital Pathology Market, 2023–2025 (USD Million)
  4. End User-Wise Revenue Breakdown for the Digital Pathology Market, 2023–2025 (USD Million)
  5. Deployment-Wise Revenue Breakdown for the Digital Pathology Market, 2023–2025 (USD Million)
  6. Digital Pathology Market Production & Volume, By Product, 2025 (active site deployments)
  7. Digital Pathology Market Size, By Region, 2025 (USD Million)
  8. North America Digital Pathology Market Size, By Country, 2023–2035 (USD Million)
  9. Europe Digital Pathology Market Size, By Country, 2023–2035 (USD Million)
  10. Asia Pacific Digital Pathology Market Size, By Country, 2023–2035 (USD Million)
  11. Latin America Digital Pathology Market Size, By Country, 2023–2035 (USD Million)
  12. The Middle East Digital Pathology Market Size, By Country, 2023–2035 (USD Million)
  13. Africa Digital Pathology Market Size, By Country, 2023–2035 (USD Million)
  14. United States Digital Pathology Market Size, 2023–2035 (USD Million)
  15. Germany Digital Pathology Market Size, 2023–2035 (USD Million)
  16. South Korea Digital Pathology Market Size, 2023–2035 (USD Million)
  17. Key Companies: HQ, Focus, Strategy and Recent Actions
  18. Recent Developments in the Digital Pathology Market, 2025–2026
  19. FDA 510(k) Clearances in Digital Pathology, 2024–2026

List of Figures (selected)

  1. Digital Pathology Market Size, 2025–2035 (USD Million)
  2. Digital Pathology Market: Drivers, Restraints, Opportunities & Challenges
  3. Digital Pathology Market Share by Region, 2025
  4. Digital Pathology Market — Segmentation Overview
  5. Digital Pathology Market Share, By Product, 2025 (%)
  6. Digital Pathology Market Share, By End User, 2025 (%)
  7. Digital Pathology Market — Product Mix by Region
  8. Digital Pathology Market — Competitive Landscape
  9. Digital Pathology Market — At a Glance
  10. United States Digital Pathology Market Size, USD Million
  11. Germany Digital Pathology Market Size, USD Million
  12. South Korea Digital Pathology Market Size, USD Million

You May Also Be Interested In

Planned

Liquid Biopsy Diagnostics Market

Shares oncology diagnostic lab buyers and the cancer-diagnosis demand pool

Published

Multi-Cancer Early Detection Market

Downstream biopsies from screening programmes feed digital pathology case volumes

Published

Telemedicine Technologies Market

Telepathology and remote sign-out run on the same connectivity and platform stack

Planned

Point-of-Care Molecular Diagnostics Market

Overlapping hospital laboratory buyers and diagnostics vendors such as Roche and Agilent

All VMI market research reports available in PDF. Contact sales@vectomatinsights.com

Frequently Asked Questions

What does the VMI Digital Pathology report include?

The report includes market sizing for 2023–2025 and forecasts to 2035, segment tables by Product, Application, End User and Deployment, a Production & Volume analysis, six regional sections with 35+ country coverage, a full drivers-restraints-opportunities-challenges analysis, a 14-company competitive table, value chain analysis, policy review and recent developments. It runs to 300+ pages with 96 tables and 70 figures, according to Vectomat Insights.

What is the Digital Pathology market size and forecast?

Vectomat Insights values the Global Digital Pathology market at USD 1,378.5 Mn in 2025 and forecasts USD 4,175.6 Mn by 2035, an 11.72% CAGR across the 2026–2035 forecast period. Hospitals & Diagnostic Labs are both the largest and fastest-growing end user, at 50.0% of 2025 revenue and a 15.14% CAGR, while Hybrid is the fastest-growing deployment model at 18.0% a year, according to Vectomat Insights.

How is the Digital Pathology market segmented in this report?

The report segments the market by Product (Software & Analytics, Scanners, Storage & Communication Systems, Services), by Application (Cancer Diagnosis, Drug Discovery & Development, Disease Research, Others), by End User (Hospitals & Diagnostic Labs, Pharma & Biotech Companies, Academic & Research Institutes) and by Deployment (On-Premise, Cloud-Based, Hybrid), plus six regions, with segment revenue tables for 2023–2025, according to Vectomat Insights.

Which countries are covered in this report?

The report covers 35+ countries across six regions: North America (U.S., Canada, Mexico), Europe (Germany, France, U.K., Italy, Spain and others), Asia Pacific (China, Japan, India, South Korea, Australia and others), Latin America (Brazil, Argentina, Colombia, Chile, Peru), the Middle East (GCC states, Israel, Turkey, Iran) and Africa (South Africa, Egypt, Nigeria, Algeria, Morocco). Detailed snapshots cover the U.S., Germany and South Korea, according to Vectomat Insights.

What customization options are available?

Buyers can request up to 10% free customization. Typical requests include extra country splits, additional company profiles, and deeper sub-segment cuts, such as scanner throughput class, AI algorithm category or cloud provider. Further custom work, including installed-base tracking or buyer surveys among pathology lab directors, is available on request through the Vectomat Insights sales team at sales@vectomatinsights.com, according to Vectomat Insights.

How can I access or purchase the Digital Pathology report?

You can request a free sample, raise a pre-purchase inquiry or buy the full Digital Pathology Market Report at www.vectomatinsights.com. The report is delivered as a PDF by email and through an online download portal, and customization requests can be agreed before purchase. For corporate licences or bulk orders, contact the team directly at sales@vectomatinsights.com for pricing and licence terms, according to Vectomat Insights.

What research methodology does VMI use for this report?

VMI combines a bottom-up model of scanner placements, software and AI licences, storage installations and service contracts with a top-down check against reported vendor revenue. Primary interviews with lab directors, hospital IT leads and vendor product managers are triangulated with FDA 510(k) and IVDR records, company filings and the 2026 Labcorp pathologist survey, and every segment and regional table is reconciled to the base-year total, according to Vectomat Insights.

Access the Complete Digital Pathology Market Report

300+ pages | 96 tables & 70 figures | 2026–2035 | All 6 regions | PDF

Contact: sales@vectomatinsights.com

About Vectomat Insights

Vectomat Insights is an independent market research firm. Our analysts build every market model in-house, from company revenues, government and regulatory data, and interviews with industry participants, and each report is reviewed by a senior analyst and fact-checked before publication.

Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com

Request a free sample

Ready to go deeper? Request a free sample of the VMI Digital Pathology Report — preview key data tables, segmentation depth, and regional forecasts before purchasing.

Your request goes straight to our sales team. We reply within one business day. Details are used only to answer this request (see our privacy policy).

About this report

Analyst team
Sneha Reddy
Sneha Reddy
Author · Senior Research Analyst

Sneha Reddy is a Senior Research Analyst at Vectomat Insights with more than 13 years of experience in market research and industry analysis, focused on healthcare and pharmaceutical intelligence.

Sunil Bhosale
Sunil Bhosale
Reviewer · Senior Research Manager

Sunil Bhosale is a Senior Research Manager at Vectomat Insights and a market research and intelligence professional with expertise in market sizing, forecasting, competitive intelligence and strategic analysis across pharmaceutical and healthcare markets.

Meet the research team →
Cite this reportVectomat Insights. (2026). Digital Pathology Market Report, 2026–2035. Retrieved from https://www.vectomatinsights.com/report/digital-pathology-market